EXACT Sciences Corporation Stock News

Exact Sciences (EXAS) has pre-announced first quarter results, with total revenue up 114% year-over-year at $348 million, surpassing the Street estimate of $342.6 million.The company, which focuses on

In a report released yesterday, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Exact Sciences (EXAS), with a price target of $115.00. The

In a report released yesterday, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Exact Sciences ( EXAS – Research Report ), with a price target of $115.00 . The company’s shares closed las

Exact Sciences is a leading player in tissue and liquid-based minimally invasive cancer diagnostics space. The company has robust financial profile. Investors s

Guggenheim Capital LLC increased its stake in EXACT Sciences Co. (NASDAQ:EXAS) by 29.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchang

Allworth Financial LP bought a new stake in EXACT Sciences Co. (NASDAQ:EXAS) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 2,000 shares of the medical resea

EXACT Sciences (NASDAQ:EXAS) was downgraded by ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday, ValuEngine reports. Several other broke

Exchange Traded Concepts LLC grew its holdings in EXACT Sciences Co. (NASDAQ:EXAS) by 116.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 2,3

These two companies have exciting growth opportunities ahead and could make your money work for you.

Gofen & Glossberg LLC IL lessened its holdings in EXACT Sciences Co. (NASDAQ:EXAS) by 1.9% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fi

Artemis Investment Management LLP trimmed its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 21.5% in the first quarter, HoldingsChannel reports. The firm owned 115,748 shares of the medica

IFM Investors Pty Ltd lessened its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 2.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exc

Back-to-Back Gains Help Dow, S&P; Soar 12%+ This Week

These three developmental-stage pharma stocks are attracting some of the smartest investors right now.

The coronavirus may have temporarily slowed them down, but some businesses are built better than others to shrug off the COVID-19 contagion.